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Background: Root extracts of Withania somnifera (Ashwagandha) are known to possess analgesic, anti-
inﬂammatory and chondroprotective effects. An aqueous extract of roots plus leaves of this plant has
shown to yield higher percentages of withanolide glycosides and, accordingly, may possess better
analgesic, anti-inﬂammatory and chondroprotective effects than root alone extracts.
Objectives: To evaluate efﬁcacy and tolerability of a standardized aqueous extract of roots plus leaves of
W. somnifera in patients with knee joint pain and discomfort.
Material and methods: Sixty patients with knee joint pain and discomfort were randomized in a double-
blind manner toW. somnifera 250 mg, W. somnifera 125 mg and placebo, all given twice daily. Assessment
was done by Modiﬁed WOMAC, Knee Swelling Index (KSI), Visual Analogue Scale (VAS) at baseline and at
the end of 4, 8, 12 weeks. Tolerability was assessed by incidence of adverse effects in treatment groups.
Student's ‘t’ test and ANOVA were used to compare mean change from baseline within and between the
study groups. A p < 0.05 was considered signiﬁcant.
Results: At the end of 12 weeks, compared to baseline and placebo, signiﬁcant reductions were observed
in mean mWOMAC and KSI in W. somnifera 250 mg (p < 0.001), W. somnifera 125 mg (p < 0.05) groups.
VAS scores for pain, stiffness and disability were signiﬁcantly reduced inW. somnifera 250 mg (p < 0.001),
W. somnifera 125 mg (p < 0.01) groups. W. somnifera 250 mg group showed earliest efﬁcacy (at 4 weeks).
All treatments were well tolerated.
Conclusions: Both the doses of an aqueous extract of W. somnifera produced signiﬁcant reduction in
outcome variables, with the 250 mg group showing signiﬁcantly better response. In addition, the
therapeutic response appears to be dose-dependent and free of any signiﬁcant GI disturbances.
© 2016 Transdisciplinary University, Bangalore and World Ayurveda Foundation. Publishing Services by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
1.1. Background
Knee joint pain and discomfort are the most prevalent of the
chronic rheumatic symptoms and is a leading cause of disability
in most countries worldwide [1].The prevalence of joint pain and
discomfort due to osteoarthritis (OA) increases with age andRamakanth).
ary University, Bangalore.
lore and World Ayurveda Foundat
es/by-nc-nd/4.0/).more so with female gender, though males are also affected. OA
contributes to a higher disease burden in men below the age of
50 and in women over the age of 50 [2]. Most of the disability
arising due to OA is due to involvement of hip and knee joints
[3]. Knee OA is likely to become the fourth most important
global cause of disability in women and eighth most important
in men [4].
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are the most
commonly used drugs for the symptomatic treatment of pain in
OA. However, NSAIDs are associated with serious gastrointes-
tinal adverse effects which limit their use in many patients [5,6].
Other drugs like opioids and non-opioid analgesics and intra-
articular steroids may not be effective in all patients [5,6].ion. Publishing Services by Elsevier B.V. This is an open access article under the CC
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treatment of OA.
Herbal medicines have been explored for their usefulness in OA
for a long time. Withania somnifera (Ashwagandha), a plant
belonging to the family Solanaceae, is widely used in Ayurvedic
medicine for this purpose. It is an ingredient in many formulations
prescribed for a variety of musculoskeletal conditions (e.g.,
arthritis, rheumatism), and as a general tonic to improve overall
health [7]. Roots of the plant reportedly exhibit anti-inﬂammatory,
anti-tumour, anti-stress, antioxidant, immunomodulatory, haema-
topoietic and rejuvenating properties [8]. There is evidence of
effectiveness of W. somnifera in various rheumatologic conditions
due to its anti-inﬂammatory properties [9]. In a randomized,
double-blind, placebo-controlled, cross-over study in patients with
OA, treatment with roots of W. somnifera produced a signiﬁcant
drop in severity of pain and disability score. It also acts as an
analgesic that soothes nervous system from pain response [10].
Chemical composition of W. somnifera extracts vary widely
depending on which part of the plant is used as well as the
extraction solvent and procedure, and thus different extracts are
expected to elicit different clinical response. Sensoril® is an
aqueous extract of W. somnifera roots plus leaves and contains
withanolide glycosides, Withaferin-A and oligosaccharides as the
major components. There are very few human studies evaluating
the effects of W. somnifera root extracts, in combination with other
herbal products, in patients with symptoms of knee joint pain and
disability and there are no human studies reportedwith an aqueous
extract of roots plus leaves of W. somnifera.2. Objectives
To evaluate the efﬁcacy and tolerability of a standardized
aqueous extract of roots plus leaves ofW. somnifera using Modiﬁed
WOMAC index score, pain relief as assessed by Visual Analogue
Scale (VAS) and changes in Knee Swelling Index (KSI) in patients
with pain and discomfort of knee joint.3. Methods
3.1. Study design
The study was a prospective, randomized, double-blind, pla-
cebo-controlled trial with 1:1:1 allocation ratio of the participants
in to the 3 study groups. The study was approved by the local
Institutional Ethics Committee.3.2. Study participants
3.2.1. Eligibility criteria
The patients were screened for their eligibility to participate in
the study during the screening visit (Visit 1).
a. Inclusion Criteria
Patients with knee joint pain and discomfort of either gender
aged between 40 and 70 years, for at least 6 months duration and
meeting the American Rheumatology Association (ARA) functional
class I to III and who recorded baseline pain scores of at least
40 mm on the VAS monitored at baseline visit were enrolled.
Patients who discontinued all current analgesic therapy, including
NSAIDs, over the counter pain medications and topical analgesics
for 7e10 days prior to the start of the study were randomized into
the study.b. Exclusion Criteria
Patients with severe OA (ARA functional class IV), on alternative
system of medicine, any psychiatric disorder or who have been
using systemic/intra-articular steroids within 12 weeks of study
and hyaluronic acid in the last 9 months, or potential candidates for
imminent joint replacement and patients with uncontrolled hy-
pertension or diabetes, hepatic or renal impairment, pregnant or
lactating females, or with a recent trauma of the involved knee
were excluded from the study.3.3. Study interventions
The study medications included capsules of W. somnifera in the
strengths of 125 mg and 250 mg and identical placebo capsules,
supplied by Natreon, Inc, New Jersey, USA.
AW. somnifera capsule consists of standardized aqueous extract
of roots and leaves of W. somnifera (Sensoril®) containing not less
than 10% Withanolide glycosides, not less than 32% oligosaccha-
rides and not more than 0.5% of Withaferin- A and is standardized
by HPLC (Fig. 1). The excipients used in these capsules include
microcrystalline cellulose, croscarmellose sodium, silicon dioxide,
magnesium stearate and gelatin from the capsule shell.3.4. Study procedure
The study was conducted in the Department of Clinical Phar-
macology and Therapeutics. The patients were randomized by the
principal investigator using a computer generated simple
randomization sequence with a block size of 20 patients per group.
Case record numbers and sequentially numbered containers were
used for random allocation sequence. The study was performed in a
double-blinded manner, with both the study patients and the
investigator blinded to study interventions. The participant ﬂow
chart is shown in Fig. 2.
A run-in period was allowed between screening visit (Visit 1)
and randomization visit (Visit 2) to ensure that thewereweaned off
all medications 7e10 days prior to randomization. At the baseline/
randomization visit (Visit 2, Day 0), all eligible were randomized to
receive either W. somnifera 250 mg or W. somnifera 125 mg or
identical placebo capsules for 4 weeks, with one capsule of the
study medication to be taken twice daily after food with a glass of
water. Paracetamol 650mg tablets were used as and when required
as rescue medication. The subsequent visits were scheduled at 4
weeks interval (Visit 3-after 4 weeks of treatment initiation, Visit 4
-after 8 weeks of treatment initiation and Visit 5- after 12 weeks of
treatment initiation). The study and rescue medications were
dispensed at visits 2, 3 and 4 and compliance to study medications
was checked by pill countmethod during the subsequent visits. The
total duration for which the patients received study medications
was 12 weeks.
All the efﬁcacy variables, pill count, use of rescue medication
and Physician's Global Assessment were evaluated in the subse-
quent visits. Adverse reactions/serious adverse effect (ADR/SAE)
monitoring was done throughout the course of study. Safety lab
were done before and after treatment and as and when required.3.5. Outcomes
The primary outcome measure was percentage change in the
Modiﬁed Western Ontario and McMaster University Osteoarthritis
Index (mWOMAC, Ref. www.copcord.org/images/WOMAC.pdf)
score at the end of 12 weeks from baseline.
Fig. 1. HPLC Chromatogram of Sensoril®.
Fig. 2. Participant ﬂow chart.
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in mWOMAC score at the end of 4 and 8 weeks, Knee Swelling
Index (KSI) as measured by joint circumference (mm) and VAS
for pain, disability and stiffness at the end of 4, 8 and 12 weeks,
extent of use of rescue medication in treatment groups, Physi-
cian Global Assessment scale and tolerability. The Physician
Global Assessment was used to classify the patients based onsymptoms. Accordingly, the 5 categories were Excellent (com-
plete relief of symptoms), Good (partial relief of symptoms), Fair
(minimal relief of symptoms), Poor (no relief of symptoms) and
Very poor (worsening of symptoms). Tolerability was assessed by
3 categories, viz., Good (no side effects), Fair (mild to moderate
side effects) and Poor (severe side effects and withdrawal of
therapy).
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The sample size calculation was based on the assumption that
there will be a decrease of 10% in total mWOMAC score from
baseline to end of treatment. A sample size of 60 evaluable cases
would provide an 80% power to estimate the reduction of total
mWOMAC score at 5% level of signiﬁcance at the end of the study.
Anticipating 15% dropouts, we enrolled 70 to get 60 evaluable cases
for the study.3.7. Statistical analysis
Primary and secondary end points were analyzed as average
change in the response from baseline. Student's ‘t’ test and ANOVA
were used to compare the mean change from baseline to post-
treatment period within and between study medications and pla-
cebo groups, respectively, at 80% power. A p < 0.05 was used to test
the signiﬁcance. All statistical analysis was performed using the
GraphPad Prism Software 4 (GraphPad Software Inc., San Diego,
California, USA).4. Results
A total of seventy patients were recruited and screened over a
period of 10 months (4/7/2014 to 16/5/2015), out of which 60
eligible patients (43 males, 17 females) with a mean age of
57.78 ± 4.49 years were enrolled into the study. Patients were
divided into three groups of 20 each and were randomized to
receive W. somnifera 250 mg, W. somnifera 125 mg or identical
placebo capsules, one capsule twice daily for 12 weeks. All patients
completed 12 weeks of treatment.
The demographic characteristics of all the three study groups
are shown in Table 1. There were no signiﬁcant differences between
the treatment groups in baseline characteristics including age,
weight and body mass index, indicating a homogenous population.
The mWOMAC scores at the end of 12 weeks are shown in
Table 2(a) and the mean percentage reduction in mWOMAC scoresTable 1
Demographic data.
W. somnifera
250 mg (A)
W. somnifera
125 mg (B)
Placebo (C)
No. of Subjects 20 20 20
Gender (M/F) 13/7 14/6 16/4
Age (Yrs) 58.92 ± 6.07 55.42 ± 3.69 58.95 ± 3.73
BMI(Kg/m2) 23.79 ± 2.99 23.82 ± 1.86 24.15 ± 2.17
Table 2a
Summary of results  I.
mWOMAC score
W. somnifera 250 mg (A) W. somnifera 125 mg (B) Pla
Baseline 53.1 ± 2.90 51.15 ± 2.39 50.
End of 4 weeks 48.6 ± 2.41# 49.95 ± 2.11 49.
End of 8 weeks 43.4 ± 2.47* 47.4 ± 1.91 49.
End of 12 weeks 37.65 ± 2.41* 44.6 ± 1.42@ 48.
Absolute change at
end of 12 weeks
15.45 ± 1.73* 6.5 ± 1.23# 2.1
Mean percentage change
at end of 12 weeks
29.07 ± 2.73* 12.7 ± 1.96# 4.2
@ p value < 0.05; #p value < 0.01; *p value < 0.001 compared to baseline; NS- Non-sign
Absolute change in mWOMAC score: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).
Mean percentage change in mWOMAC score:* A vs B, A vs C (p < 0.001); #B vs C (p < 0
Absolute change in KSI: * A vs B, A vs C (p < 0.001),NS B vs C.
Mean percentage change in KSI: * A vs B, A vs C (p < 0.001), NS B vs C.are shown in Fig. 3. The baseline values of themWOMAC scorewere
comparable in all the three groups without any statistically signiﬁ-
cant difference between them. There was a signiﬁcant reduction in
the mWOMAC score at the end of 12 weeks from baseline in W.
somnifera 250 mg group (A) (p < 0.001) and W. somnifera 125 mg
group (B) (p < 0.05). The mean percentage reduction in the mWO-
MAC score at the end of 12 weeks showed signiﬁcant differences
between W. somnifera 250 mg (A) and W. somnifera 125 mg groups
(B) (p < 0.001), W. somnifera 250 mg (A) and placebo groups (C)
(p < 0.001) and W. somnifera 125 mg (B) and placebo groups (C)
(p < 0.01).
The KSI scores at the end of 12 weeks are shown in Table 2(a)
and mean percentage change in KSI scores are shown in Fig. 4. The
baseline values of the KSI scores were comparable in all the three
groups without any statistically signiﬁcant difference between
them. There was a signiﬁcant reduction in the KSI score at the end
of 12 weeks from baseline in W. somnifera 250 mg group (A)
(p < 0.001) andW. somnifera 125 mg group (B) (p < 0.05). The mean
percentage reduction in the KSI scores in all the three groups at the
end of 12 weeks showed a signiﬁcant difference between W. som-
nifera 250 mg (A) and W. somnifera 125 mg (B) groups (p < 0.001)
and W. somnifera 250 mg (A) and placebo (C) groups (p < 0.001).
The VAS score for pain, stiffness and disability are shown in
Table 2(b) and the mean percentage changes in these scores are
shown in Figs. 5e7, respectively. The baseline values for pain, stiff-
ness and disability measured by VAS were comparable in all theFig. 3. Mean percentage change in modiﬁed WOMAC score at the end of 12 weeks.
Knee swelling index
cebo (C) W. somnifera 250 mg (A) W. somnifera 125 mg (B) Placebo (C)
45 ± 2.11 423.25 ± 9.63 415.5 ± 20.76 408.5 ± 15.05
97 ± 2.04 415.25 ± 9.66# 413.75 ± 19.65 404.6 ± 15.30
31 ± 2.11 404.75 ± 10.44* 409.25 ± 19.61 401 ± 15.61
24 ± 2.31 396.25 ± 10.98* 405.75 ± 19.21@ 399.5 ± 15.55
5 ± 0.75 27 ± 6.76* 9.75 ± 3.43NS 9 ± 2.62
7 ± 1.46 6.37 ± 1.58* 2.34 ± 0.78NS 2.2 ± 0.65
iﬁcant.
.01).
Fig. 4. Mean percentage change in knee swelling index score at the end of 12 weeks.
Fig. 5. Mean percentage change in VAS e pain score at the end of 12 weeks.
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tween them. In W. somnifera 250 mg group (A), there was a signiﬁ-
cant reduction in pain, stiffness and disability (p < 0.001) at the end
of 12 weeks from baseline. In W. somnifera 125 mg group (B), there
was a signiﬁcant reduction in pain (p< 0.01), stiffness (p< 0.01) and
disability (p < 0.05). The mean percentage reduction in the pain,
stiffness and disability in all the three groups at the end of 12weeks
showed a signiﬁcant difference between W. somnifera 250 mg (A)
and W. somnifera 125 mg (B) groups (p < 0.001) and W. somnifera
250 mg (A) and placebo (C) groups (p < 0.001) and W. somnifera
125 mg (B) and placebo (C) groups (p < 0.01).
5. Rescue medication usage
The mean number of rescue medication tablets (Paracetamol
650 mg) was 10, 13 and 17 inW. somnifera 250 mg (A),W. somnifera
125 mg (B) and placebo (C) groups, respectively.
6. Physician Global Assessment
The Physician Global Assessment was done at the end of 12
weeks. In W. somnifera 250 mg group, 15 patients were assessed toTable 2b
Summary of results  II.
VAS, pain VAS, stiffne
W. somnifera
250 mg (A)
W. somnifera
125 mg (B)
Placebo (C) W. somnife
250 mg (A)
Baseline 67.25 ± 4.48 65.6 ± 4.56 63.8 ± 2.78 60.25 ± 4.1
End of 4 weeks 60.95 ± 4.22# 63.05 ± 4.67 60.5 ± 3.24 55.8 ± 3.83
End of 8 weeks 52.9 ± 3.37* 59.5 ± 4.07 58.65 ± 3.56 49.4 ± 3.28
End of 12 weeks 43.9 ± 3.30* 53.3 ± 4.02# 57.4 ± 3.68 41.3 ± 3.54
Absolute change at
end of 12 weeks
23.35 ± 3.04* 12 ± 2.31# 6.4 ± 1.57 18.95 ± 3.0
Mean percentage change
at end of 12 weeks
34.73 ± 3.49* 18.29 ± 3.13# 10.08 ± 2.71 31.4 ± 4.26
@ p value < 0.05; #p value < 0.01; *p value < 0.001 compared to baseline.
Absolute change in VAS scores:
a) Pain: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).
b) Stiffness: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).
c) Disability: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).
Mean percentage change in VAS scores:
a) Pain: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).
b) Stiffness: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).
c) Disability: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).be excellent and 5 were assessed as good by the Physician Global
Assessment scale.
In W. somnifera 125 mg group, 17 patients were assessed to be
good and 3 were assessed as fair and in the placebo group,1 patient
was assessed to be fair and 19 patients were assessed as poor.7. Results at 4 and 8 weeks
At the end of 4weeks, patients treatedwithW. somnifera 250mg
twice daily showed statistically signiﬁcant reductions in the
mWOMAC score (p < 0.01), KSI (p < 0.01), pain (p < 0.01), stiffness
(p < 0.01) and disability (p < 0.01) as measured by VAS when
compared to baseline. However, patients treated withW. somnifera
125 mg twice daily did not show any signiﬁcant changes at the end
of 4 weeks compared to baseline.
At the end of 8 weeks, patients treated with W. somnifera
250mg showed statistically signiﬁcant reductions in themWOMAC
score (p < 0.001), KSI (p < 0.001), pain (p < 0.001), stiffness
(p < 0.001) and disability (p < 0.001) as measured by VAS,
compared to baseline. W. somnifera 125 mg (B) showed signiﬁcantss VAS, disability
ra W. somnifera
125 mg (B)
Placebo (C) W. somnifera
250 mg (A)
W. somnifera
125 mg (B)
Placebo (C)
1 62.55 ± 4.43 61.8 ± 2.71 50.45 ± 4.35 63.95 ± 4.71 58.6 ± 4.30
# 59.45 ± 4.13 58.6 ± 2.85 46 ± 3.98# 61 ± 5.03 55.35 ± 4.06
* 56.3 ± 4.05 @ 56.7 ± 2.96 40.35 ± 3.64* 57.75 ± 5.03 53.5 ± 4.42
* 50.1 ± 4.12# 55.2 ± 2.98 33.55 ± 3.79* 52.6 ± 5.37@ 51.87 ± 4.48
8* 12.45 ± 2.08# 6.6 ± 1.82 17.4 ± 3.08* 11.35 ± 1.56# 6.5 ± 1.79
* 19.9 ± 3.15# 10.67 ± 2.93 33.7 ± 3.37* 17.74 ± 3.13# 11.15 ± 3.18
Fig. 6. Mean percentage change in VAS e stiffness score at the end of 12 weeks.
Fig. 7. Mean percentage change in VAS e disability score at the end of 12 weeks.
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(p < 0.05).
There were no signiﬁcant changes in the efﬁcacy variables in the
placebo group at the end of 4 and 8 weeks. The results at the end of
4 and 8 weeks are summarized in Tables 2(a), 2(b).
8. Safety and tolerability
All safety hematological and biochemical variables were within
normal limits in all the three treatment groups at the baselinerecording. BothW. somnifera 250mg andW. somnifera 125mgwere
well tolerated. In W. somnifera 250 mg group, 4 patients com-
plained of nausea and 1 patient developed mild gastritis. In W.
somnifera 125 mg group, 2 patients complained of nausea and mild
headache. None of the patients in placebo group had any adverse
effects. No patients in any of the groups discontinued the study.
9. Discussion
W. somnifera has multiple bioactive components which
contribute to it's biological activity as an analgesic, anti-
inﬂammatory, anti-arthritic and chondroprotective [11]. The
chemical analysis ofW. somnifera shows its main constituents to be
alkaloids and steroidal lactones. The biologically active alkaloids
include withanine, somniferine, somnine, isopelletierine and
anferine, and the steroidal lactones include withanolides and
withaferins [12,13]. The roots and leaves of W. somnifera have been
shown to be rich in withanolides, which resemble steroids in their
action and are considered to account for the biological activities of
W. somnifera. Other components include saponins like sitoindoside
VII and VIII and iron. Much of W. somnifera's pharmacological ac-
tivity has been attributed to Withaferin A and Withanolide D [13].
However, chemical composition of W. somnifera extracts vary
widely depending on which part of the plant is used as well as the
extraction solvent and procedure, and thus are expected to elicit
different clinical response. Sensoril® is an aqueous extract of W.
somnifera roots plus leaves and contains withanolide glycosides,
Withaferin-A and oligosaccharides as the major components.
In the present study, the mWOMAC score was reduced
signiﬁcantly at the end of 12 weeks from baseline in both W.
somnifera 250 mg and W. somnifera 125 mg groups, with the
reduction being greater in W. somnifera 250 mg group. This
reduction in mWOMAC scores by W. somnifera may be attributed
to its analgesic and chondroprotective effects. The analgesic ac-
tivity of W. somnifera is mainly mediated by Withaferin A which
has been shown to block the cyclo-oxygenase (COX) pathway
involved in the production of prostaglandins, the endogenous
pain mediators [14]. The analgesic activity is also due to its action
of soothing the nervous system from pain responses [15]. Also it
is suggested that serotonin may be involved in the analgesic ef-
fects of W. somnifera [16]. An experimental study has demon-
strated the chondroprotective activity of W. somnifera in human
cartilage tissue [17].
Another important biological effect of W. somnifera is its anti-
inﬂammatory activity which can be determined by its effect on
the KSI. The KSI scores were signiﬁcantly reduced at the end of 12
weeks from baseline in bothW. somnifera 250 mg andW. somnifera
125 mg groups. However, greater reduction was seen in W. som-
nifera 250 mg group. This anti-inﬂammatory effect of W. somnifera
has also been attributed to Withaferin A [18]. The possible role of
anti-oxidant activity of W. somnifera on its anti-inﬂammatory
properties has also been proposed. An experimental study in rats
has shown that the anti-inﬂammatory activity of W. somnifera may
be due to the inhibition of biological changes like increase in levels
of lipid peroxides and glycoproteins and decreased antioxidant
status and bone collagen in the affected joint [19]. In the affected
joint, reactive oxygen species are known to activate a number of
intracellular signaling pathways such as NF-kB (nuclear factor
kappa-light-chain-enhancer of activated B cells), which further
activate the transcription of various pro-inﬂammatory cytokines
(interleukins and TNFa), cell adhesion molecules and COX 2 [20].
Some of the constituents of W. somnifera like ﬂavonoids and
phenolic acid such as gallic acid, rutein, vanillic acid, quercetin and
kaempferol block the distinct signal transduction events necessary
for NF-kB activation and thus inhibit transcription factors such as
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related factor 2 (Nrf2) [21].
VAS scores for pain, stiffness and disability were used to assess
the physical function of the knee joint.W. somnifera, in both 250mg
and 125 mg twice daily doses, signiﬁcantly reduced the pain,
stiffness and disability at the end of 12 weeks. However, the extent
of reduction of these variables was higher with W. somnifera
250 mg twice daily dose. Also, the mean percentage reduction in all
the three variables at the end of 12 weeks was signiﬁcant with W.
somnifera 250 mg, when compared to W. somnifera 125 mg and
placebo groups.
The clinical assessment of patients with knee joint pain and
discomfort was made by the Physician Global Assessment scale.
Accordingly, patients in W. somnifera 250 mg group were assessed
to have performed better in terms of clinical improvement
compared to the other two groups.
Rescue medication in the form of Paracetamol 650 mg was
allowed as and when required during the course of the study. We
evaluated the usage of rescue medication as one of the outcomes
measures of efﬁcacy ofW. somnifera treatment. The usage of rescue
medication was the least in W. somnifera 250 mg group and the
highest in the placebo group, indicating effectiveness of W. som-
nifera in reducing the symptoms of knee joint pain and discomfort.
The efﬁcacy was also evaluated at 4 weeks and 8 weeks to
determine the earliest onset of action. At the end of 4 and 8 weeks,
patients treated with W. somnifera 250 mg twice daily showed
statistically signiﬁcant reductions in all efﬁcacy variables,
compared to baseline. However, patients treated withW. somnifera
125 mg twice daily did not show any signiﬁcant changes at the end
of 4 weeks compared to baseline and showed only signiﬁcant
change in VAS stiffness (p < 0.05) at the end of 8 weeks, compared
to baseline. This suggests that treatment withW. somnifera 250 mg
twice daily produces earlier and better symptomatic relief thus
increasing patient compliance and satisfaction. In addition, the
response with W. somnifera seems to be linearly dose-dependent.
The safety of W. somnifera was evaluated by monitoring the
occurrence of any adverse effects. BothW. somnifera 250 mg andW.
somnifera 125 mg were well tolerated and our study did not report
any serious adverse effects with either of the doses ofW. somnifera.
This is consistent with the available literature on safety of W.
somnifera [22]. Gastritis, nausea and headache that were reported
were treated symptomatically with standard care of treatment.
10. Conclusions
Treatment with W. somnifera 250 mg and W. somnifera 125 mg,
both taken twice daily in patients with knee joint pain and
discomfort for a period of 12 weeks showed signiﬁcant reduction in
the outcome variables of efﬁcacy and safety, when compared to
baseline and placebo. On further analysis, W. somnifera 250 mg
produced better reduction in outcomes when statistically
compared toW. somnifera 125 mg. Also, this effect was seen earlier
(in 4 weeks) in W. somnifera 250 mg group than in W. somnifera
125 mg group. The need for rescue medication (Paracetamol
650 mg tablets) was the least with W. somnifera 250 mg group
suggesting its analgesic and anti-inﬂammatory effects. All the study
medications were well tolerated and mild gastrointestinal adverse
effects like nausea and gastritis were observed in few patients.
None of the patients discontinued the study suggesting the favor-
able safety proﬁle of W. somnifera. Further studies with W. somni-
fera, hence, are needed to conﬁrm its therapeutic potential inpatients with knee joint pain and discomfort and other painful
rheumatologic conditions.
Registration of the trial
The trial was registered in the Clinical Trial Registry-India (CTRI)
with the reference number REF/2014/08/007385.
Conﬂict of interest
None.
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